title: Hungry bone syndrome.
abstract: In the United States, the number of parathyroidectomies among patients with chronic dialysis has remained stable in the last decade. A fall in serum calcium concentration is common postparathyroidectomy in patients with hyperparathyroidism, which usually resolves in 2-4 days. A severe drop in serum total calcium concentration less than 2.1 mmol/L and/or prolonged hypocalcemia for more than 4 days postparathyroidectomy is called hungry bone syndrome (HBS). Concomitant hypophosphatemia, hypomagnesemia, and hyperkalemia can be seen. Hypocalcemia and hypophosphatemia can persist for months to years. In contemporary clinical practice, HBS may be more commonly seen in patients with secondary compared to primary hyperparathyroidism. Preoperative radiological changes in bone, elevated serum alkaline phosphatase and parathyroid hormone (PTH) levels, and high numbers of osteoclasts on bone biopsy may identify patients at risk. Treatment consists of high-dose oral calcium and calcitriol supplementation. A low-dose pamidronate infusion 1-2 days prior to surgery may prevent HBS.
  
  
  
  Recent in-vitro studies reported net calcium movement into bone because of a sudden fall in serum PTH level after a prolonged period of elevation. This supports a previous hypothesis that a sudden drop in serum PTH level after surgery results in the unopposed action of osteoblasts and influx of calcium into bone.
  
  
  
  Incidence of HBS and its association with morbidity and mortality remains unclear in contemporary clinical practice. It is more common to encounter HBS in chronic dialysis patients with secondary hyperparathyroidism than those with primary hyperparathyroidism that undergo parathyroidectomies. Use of bisphosphonates to prevent HBS should be explored in future studies.
authors.affiliation: aDivision of Nephrology, University of Arkansas for Medical Sciences bCentral Arkansas Veterans Affairs Healthcare System, Little Rock, Arkansas cOffice of Education, Central Alabama Veterans Healthcare System, Montgomery, Alabama, USA.
authors.forename: Nishank
authors.initials: N
authors.lastname: Jain
authors.forename: Robert F
authors.initials: RF
authors.lastname: Reilly
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001851:Bone Diseases, Metabolic / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D006961:Hyperparathyroidism / Q000209:etiology / Q000601:surgery*; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000601:surgery; D006996:Hypocalcemia / Q000175:diagnosis* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000628:therapy; D000077268:Pamidronate; D016105:Parathyroidectomy / Q000009:adverse effects*; D006435:Renal Dialysis / Q000009:adverse effects*; D013577:Syndrome
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D002117:Calcitriol; D000077268:Pamidronate; D002118:Calcium